These findings demonstrate that JXGT treatment has a potential protection on HFD-induced obesity mice via activating the AMPK/CPT-1A and down-regulating FAS/GSK-3β/PGC-1α and IL-6/TNFα. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.